Last reviewed · How we verify
Aurobindo Pharma Limited — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE | DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE | marketed | Other |
Therapeutic area mix
- Other · 1
Recent regulatory actions (last 90 days)
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
- — DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Aurobindo Pharma Limited:
- Aurobindo Pharma Limited pipeline updates — RSS
- Aurobindo Pharma Limited pipeline updates — Atom
- Aurobindo Pharma Limited pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Aurobindo Pharma Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/aurobindo-pharma-limited. Accessed 2026-06-10.